Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects

• Published in: Journal of clinical pharmacology Vol. 52; no. 3; p. 319
• Main Authors: Chen, Dawn, Whitcomb, Randall, MacIntyre, Euan, Tran, Vinh, Do, Zung N, Sabry, James, Patel, Dinesh V, Anandan, Sampath K, Gless, Richard, Webb, Heather K
• Format: Journal Article
• Language: English
• Published: England 01.03.2012
• Subjects: Adamantane - adverse effects; Adamantane - analogs & derivatives; Adamantane - blood; Adamantane - pharmacokinetics; Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epoxide Hydrolases - antagonists & inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Urea - adverse effects; Urea - analogs & derivatives; Urea - blood; Urea - pharmacokinetics; Young Adult

AR9281, a potent and selective inhibitor of soluble epoxide hydrolase (s-EH), is in clinical development targeting hypertension and type 2 diabetes. The safety, pharmacokinetics, and pharmacodynamics of AR9281 were evaluated in double-blind, randomized, placebo-controlled, ascending, single oral dos...